ReviewRSC advances2021
Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects.
Review in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 83 citations in OpenAlex.
- Biogenic Zinc Oxide Nanoparticles for Skin Disorders: Mechanistic Insights, Translational Challenges, and Future Prospects.Biological trace element research · 2026Review
- Dissolving microneedle delivery of anemoside B4: a strategy to enhance therapeutic efficacy against psoriasis.Drug delivery and translational research · 2026Article
- Nose-to-Brain Nanocarriers for Migraine Management: A Comprehensive Review of Drug Delivery Strategies and Translational Challenges.Current medical science · 2026Review
- Shikonin-Loaded ROS-Responsive Microneedles for Psoriasis Therapy: Formulation, Transdermal Delivery, and Mechanistic Evaluation.Pharmaceutics · 2026Article
- Nanotechnology in Dermatology: A Comprehensive Narrative Review of Performance, Safety, and Clinical Translation.Health science reports · 2026Article
- Review
- Structurally Modified Cyclodextrins in Topical Nanotechnology: Advancing Barrier-Penetrating Drug Delivery Strategies for Psoriasis Management.AAPS PharmSciTech · 2026Review
- Curcumin-loaded nanocarriers for dermatological applications: current advances and biomedical implications.EXCLI journal · 2026Review
- Application of Trichoscopy and Novel Non-Invasive Imaging Techniques in the Diagnosis and Management of Patients with Scalp Psoriasis.Psoriasis (Auckland, N.Z.) · 2026Review
- Revolutionizing rheumatoid arthritis therapy: the potential of lipid nanocarriers.RSC advances · 2025Review
- Exploring the Therapeutic Potential of Lipid Nanocarriers in Psoriasis Management: Advances and Applications.AAPS PharmSciTech · 2025Review
- Tapinarof Nanogels as a Promising Therapeutic Approach.Pharmaceutics · 2025Review
- Berberine hydrochloride-loaded liposomes-in-hydrogel microneedles achieve the efficient treatment for psoriasis.Materials today. Bio · 2025Article
- Advances in the Drug Delivery Systems for Psoriasis Topical Therapy.International journal of nanomedicine · 2025Review
- miRNAs and exosomes in psoriasis: coordinating cytoskeleton dynamics and extracellular matrix remodeling.Frontiers in cell and developmental biology · 2025Review
- A Mini-Review on the Symptoms and Pathogenesis of Psoriasis and Recent Nanotechnological Developments in its Treatment Strategies.Current pharmaceutical design · 2025Review
- Liposomes and Their Therapeutic Applications in Enhancing Psoriasis and Breast Cancer Treatments.Nanomaterials (Basel, Switzerland) · 2024Review
- Exploring the Therapeutic Potential of Natural Compounds in Psoriasis and Their Inclusion in Nanotechnological Systems.Antioxidants (Basel, Switzerland) · 2024Review
- Coencapsulation of Immunosuppressive Drug with Anti-Inflammatory Molecule in Pickering Emulsions as an Innovative Therapeutic Approach for Inflammatory Dermatoses.JID innovations : skin science from molecules to population health · 2024Article
- Development and Optimization of Dipyridamole- and Roflumilast-Loaded Nanoemulsion and Nanoemulgel for Enhanced Skin Permeation: Formulation, Characterization, and In Vitro Assessment.Pharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a lingering inflammatory skin disease that attacks the immune system. The abnormal interactions between T cells, immune cells, and inflammatory cytokines causing the epidermal thickening. International guidelines have recommended topical treatments for mild to moderate psoriasis whilst systemic and phototherapy treatments for moderate to severe psoriasis. However, current therapeutic approaches have a wider extent to treat moderate to severe type of psoriasis especially since the emergence of diverse biologic agents. In the meantime, topical delivery of conventional treatments has prompted many unsatisfactory effects to penetrate through the skin (stratum corneum). By understanding the physiology of stratum corneum barrier functions, scientists have developed different types of lipid-based nanoparticles like solid lipid nanoparticles, nanostructured lipid carriers, nanovesicles, and nanoemulsions. These novel drug delivery systems help the poorly solubilised active pharmaceutical ingredient reaches the targeted site seamlessly because of the bioavailability feature of the nanosized molecules. Lipid-based nanoparticles for psoriasis treatments create a paradigm for topical drug delivery due to their lipids' amphiphilic feature to efficiently encapsulate both lipophilic and hydrophilic drugs. This review highlights different types of lipid-based nanoparticles and their recent works of nano formulated psoriasis treatments. The encapsulation of psoriasis drugs through lipid nanocarriers unfold numerous research opportunities in pharmaceutical applications but also draw challenges for the future development of nano drugs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.